Companies
/Healthcare
aTyr Pharma, Inc.
$0.13
▲ $0.00 (+3.55%) today
Markets closed · 3:51am ET
ATYR at a Glance
Valuation
- Market cap
- $12.2M
Profitability
- Revenue (TTM)
- $190,000
- EPS (TTM)
- $-0.62
Price
- 52-week range
- $0 – $5
- Street target
- $2.86
Earnings
- Next report
- Nov 5, 2026
Headquartered in San Diego, CA Fiscal year ends December NASDAQ: ATYR atyrpharma.com
About aTYR Pharma
aTyr Pharma is a clinical-stage biotechnology company focused on the discovery and development of first-in-class medicines derived from its proprietary tRNA synthetase platform. The company's lead therapeutic candidate is efzofitimod, a novel biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), including pulmonary sarcoidosis and systemic sclerosis-related ILD (SSc-ILD). Efzofitimod selectively modulates activated myeloid cells through neuropilin-2 to resolve inflammation without immune suppression and potentially prevent fibrosis progression. aTyr's discovery platform leverages evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation, utilizing a proprietary library of domains derived from all 20 tRNA synthetases. The company is pre-revenue and trades on Nasdaq under the ticker ATYR. Updated
Frequently Asked Questions
What does aTYR Pharma do?
aTyr Pharma is a clinical-stage biotechnology company focused on the discovery and development of first-in-class medicines derived from its proprietary tRNA synthetase platform.
What is the ATYR stock price target?
The Wall Street consensus 12-month price target for ATYR is $2.86.